ArticleAntimicrobial agents and chemotherapy2019
Article in Antimicrobial agents and chemotherapy, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 24 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
24 citing papers in PubMed.
- Assessment of pharmacokinetics-pharmacodynamics to support omadacycline dosing regimens for the treatment of patients with acute bacterial skin and skin structure infections.Antimicrobial agents and chemotherapy · 2024Trial
- Next-generation hybrid bioanalytical platforms and clinical integration of TDM technologies for precision monitoring to optimize last-resort antibiotic therapy.Frontiers in pharmacology · 2026Review
- PreclinicalAntimicrobial agents and chemotherapy · 2025Article
- Omadacycline Pharmacokinetics: Characteristics, Contributing Factors, and Clinical Significance.Drugs in R&D · 2025Review
- LC-MS/MS quantification of omadacycline in human plasma for therapeutic drug monitoring: method development and clinical application.Scientific reports · 2025Article
- A Review of Omadacycline for Potential Utility in the Military Health System for the Treatment of Wound Infections.Military medicine · 2024Review
- Article
- Evaluation of Omadacycline Alone and in Combination with Rifampin against Staphylococcus aureus and Staphylococcus epidermidis in anAntimicrobial agents and chemotherapy · 2023Article
- Article
- Re-establishing the utility of tetracycline-class antibiotics for current challenges with antibiotic resistance.Annals of medicine · 2022Review
- Real-World, Multicenter Case Series of Patients Treated with Oral Omadacycline for Resistant Gram-Negative Pathogens.Infectious diseases and therapy · 2022Article
- Omadacycline pharmacokinetics and soft-tissue penetration in diabetic patients with wound infections and healthy volunteers using in vivo microdialysis.The Journal of antimicrobial chemotherapy · 2022Article
- Omadacycline Oral Dosing and Pharmacokinetics in Community-Acquired Bacterial Pneumonia and Acute Bacterial Skin and Skin Structure Infection.Clinical drug investigation · 2022Review
- Activity of Omadacycline in Rat Methicillin-Resistant Staphylococcus aureus Osteomyelitis.Antimicrobial agents and chemotherapy · 2022Article
- Potency of Omadacycline against Mycobacteroides abscessus Clinical IsolatesAntimicrobial agents and chemotherapy · 2022Article
- Use of oral tetracyclines in the treatment of adult outpatients with skin and skin structure infections: Focus on doxycycline, minocycline, and omadacycline.Pharmacotherapy · 2021Review
- Folate Functionalized Lipid Nanoparticles for Targeted Therapy of Methicillin-ResistantPharmaceutics · 2021Article
- Efficacy of Omadacycline against Multidrug-Resistant Enterococcus faecium Strains in a Mouse Peritonitis Model.Antimicrobial agents and chemotherapy · 2021Article
- Present and Future Perspectives on Therapeutic Options for Carbapenemase-ProducingMicroorganisms · 2021Review
- Pharmacokinetic-Pharmacodynamic Characterization of Omadacycline against Haemophilus influenzae Using a One-CompartmentAntimicrobial agents and chemotherapy · 2020Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Omadacycline is a novel aminomethylcycline antibiotic with potent activity against
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.